BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19239229)

  • 1. Kinase domain mutations in cancer: implications for small molecule drug design strategies.
    Bikker JA; Brooijmans N; Wissner A; Mansour TS
    J Med Chem; 2009 Mar; 52(6):1493-509. PubMed ID: 19239229
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 4. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS: target for cancer therapy.
    Saxena N; Lahiri SS; Hambarde S; Tripathi RP
    Cancer Invest; 2008 Nov; 26(9):948-55. PubMed ID: 18798058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 8. Approval heralds new generation of kinase inhibitors?
    Fletcher L
    Nat Biotechnol; 2001 Jul; 19(7):599-600. PubMed ID: 11433254
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: from bench to clinic.
    Paris M; Porcelloni M; Binaschi M; Fattori D
    J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
    [No Abstract]   [Full Text] [Related]  

  • 10. Telomeres and telomerase as targets for anticancer drug development.
    Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical genetic approaches to kinase drug discovery.
    Gallion SL; Qian D
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-protein interactions as targets for small-molecule therapeutics in cancer.
    White AW; Westwell AD; Brahemi G
    Expert Rev Mol Med; 2008 Mar; 10():e8. PubMed ID: 18353193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 14. Turning promiscuous kinase inhibitors into safer drugs.
    Zhang X; Crespo A; Fernández A
    Trends Biotechnol; 2008 Jun; 26(6):295-301. PubMed ID: 18403035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling of phosphofructokinase from Entamoeba histolytica for the prediction of new antiparasitic agents.
    Byington CL; Dunbrack RL; Cohen FE; Agabian N
    Arch Med Res; 1997; 28 Spec No():86-8. PubMed ID: 9033023
    [No Abstract]   [Full Text] [Related]  

  • 16. Cell division on-off switches sought as targets for cancer drugs.
    Hampton T
    JAMA; 2005 Apr; 293(15):1847. PubMed ID: 15840846
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
    J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, selection, and evaluation of a general kinase-focused library.
    Decornez H; Gulyás-Forró A; Papp A; Szabó M; Sármay G; Hajdú I; Cseh S; Dormán G; Kitchen DB
    ChemMedChem; 2009 Aug; 4(8):1273-8. PubMed ID: 19551802
    [No Abstract]   [Full Text] [Related]  

  • 19. American Chemical Society--229th National Meeting. Kinase modulators.
    Mackonochie M; Chan D
    IDrugs; 2005 Apr; 8(4):283-4. PubMed ID: 15800796
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of farnesyltransferase: a rational approach to treat cancer?
    Puntambekar DS; Giridhar R; Yadav MR
    J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.